Ani Pharmaceuticals (ANIP) Preferred Stock Liabilities (2021 - 2025)
Historic Preferred Stock Liabilities for Ani Pharmaceuticals (ANIP) over the last 6 years, with Q2 2025 value amounting to $24.8 million.
- Ani Pharmaceuticals' Preferred Stock Liabilities changed 0.0% to $24.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $24.8 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $24.8 million for FY2024, which is 0.0% changed from last year.
- Per Ani Pharmaceuticals' latest filing, its Preferred Stock Liabilities stood at $24.8 million for Q2 2025, which was down 0.0% from $24.8 million recorded in Q1 2025.
- Over the past 5 years, Ani Pharmaceuticals' Preferred Stock Liabilities peaked at $24.8 million during Q4 2021, and registered a low of $24.8 million during Q4 2021.
- Over the past 5 years, Ani Pharmaceuticals' median Preferred Stock Liabilities value was $24.8 million (recorded in 2021), while the average stood at $24.8 million.
- Examining YoY changes over the last 5 years, Ani Pharmaceuticals' Preferred Stock Liabilities showed a top increase of 0.0% in 2022 and a maximum decrease of 0.0% in 2022.
- Ani Pharmaceuticals' Preferred Stock Liabilities (Quarter) stood at $24.8 million in 2021, then changed by 0.0% to $24.8 million in 2022, then changed by 0.0% to $24.8 million in 2023, then changed by 0.0% to $24.8 million in 2024, then changed by 0.0% to $24.8 million in 2025.
- Its Preferred Stock Liabilities was $24.8 million in Q2 2025, compared to $24.8 million in Q1 2025 and $24.8 million in Q4 2024.